Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding.

Abstract

BACKGROUND:

As efforts intensify to eliminate perinatal HIV transmission, understanding kinetics of maternal-to-child transfer of antiretrovirals during pregnancy and breastfeeding is critical. Antiretroviral levels in plasma, cord blood, and breastmilk reflect exposure over short intervals. Hair concentrations reflect cumulative exposure and can uniquely quantify in utero transfer of maternal medications to infants. We measured plasma and hair antiretroviral levels in HIV-infected Ugandan mothers and their infants at delivery and during breastfeeding to assess transfer.

METHODS:

HIV-infected pregnant women were randomized to lopinavir/ritonavir- or efavirenz-based therapy in a larger trial (the Prevention of Malaria and HIV disease in Tororo, PROMOTE). At 0, 8, and 12 weeks postpartum, plasma antiretroviral levels were measured in 117 mother-infant pairs; hair levels were assayed at 12 weeks. Ratios and correlations of infant:maternal concentrations were calculated.

RESULTS:

By 12 weeks, 90.4% of mothers reported exclusive breastfeeding. Hair and plasma levels over time suggest moderate (47%) to extensive (87%) in utero transfer of lopinavir and ritonavir, respectively, but negligible transfer of either via breastfeeding. Moderate transfer of efavirenz occurs during pregnancy and breastfeeding (40% cumulative; 15% during breastfeeding). Despite differences in exposure, no infant seroconversions or correlations between infant hair/plasma antiretroviral levels and adverse effects were observed.

CONCLUSIONS:

Using a unique approach combining hair and plasma data, we found that different antiretrovirals have distinct kinetics of mother-to-infant transfer. Efavirenz transfers during both pregnancy and breastfeeding, whereas lopinavir and ritonavir transfer only in utero. Further study of the degree and timing of maternal-to-child transfer by antiretroviral will help optimize strategies that protect infants and minimize toxicities during periods of risk.

• Authors: Monica Gandhi, Julia Mwesigwa, Francesca Aweeka, Albert Plenty, Edwin Charlebois, Theodore D Ruel, Yong Huang, Tamara Clark, Veronica Ades, Paul Natureeba, Flavia A Luwedde, Jane Achan, Moses R Kamya, Diane V Havlir, Deborah Cohan, Prevention of Malaria and HIV disease in Tororo (PROMOTE) study
• Journal: Journal of acquired immune deficiency syndromes (1999) (J Acquir Immune Defic Syndr) Vol. 63 Issue 5 Pg. 578-84 (Aug 15 2013) ISSN: 1944-7884 [Electronic] United States
• PMID: 24135775 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)

Chemical References

• Alkynes
• Anti-HIV Agents
• Benzoxazines
• Cyclopropanes
• Lopinavir
• efavirenz
• Ritonavir

Topics

• Alkynes
• Anti-HIV Agents (administration & dosage, pharmacokinetics)
• Benzoxazines (administration & dosage, pharmacokinetics)
• Cyclopropanes
• Female
• HIV Infections (drug therapy)
• Hair (chemistry)
• Humans
• Infant
• Infant, Newborn
• Lopinavir (administration & dosage, pharmacokinetics)
• Milk, Human (chemistry)
• Plasma (chemistry)
• Pregnancy
• Pregnancy Complications, Infectious (drug therapy)
• Ritonavir (administration & dosage, pharmacokinetics)
• Uganda